Draft of Delegated Act regarding Safety Features published
Recommendation
18 June 2024
Barcelona, Spain
The European Union has published the draft of the delegated act. This document deals with the technological and organisational requirements for the safety features that have to be considered in the future for prescription medicines in accordance with the counterfeiting directive.
The document contains 34 pages, and, in addition the Annexes I - IV.
In the future a system is proposed to be established which ensures the identification and authentication of medicinal product by an "end-to-end" verification. For certain medicinal products with a higher counterfeiting risk additional verifications are proposed to take place at the wholesalers.
As characteristic a two-dimensional (2D) barcode is supposed to be used - which must be attached to the packaging in readable form.
The monitoring authorities will also be allowed to get access to the information regarding the security characteristics of the medicinal product.
Chapter I defines which medicinal product must bear this safety feature. The technical specifications are presented in Chapter 2. The two-dimensional bar code shall comply with at least the quality of the data matrix code ECC200 and shall be of adequate quality. The more detailed requirements can be found in Chapter 6.
For further details please see the complete draft of the Commission Delegated Regulation (EU).
Related GMP News
14.03.2024New USP Chapter on Cured Silicone Components
07.12.2023First Electronic Product Information (ePI) for Human Medicines
26.10.2023Revised USP Chapter <660> Glass Containers
19.07.2023Auxiliary Packaging Components
11.07.2023How to determine the Protective Properties of Amber Glass Containers?
04.05.2023New Definition of Pharmaceutical Grade Plastic Packaging Materials